LES STENTS BIORESORBABLES: UN AVENIR ? Ren Koning St Hilaire, Rouen - - PowerPoint PPT Presentation

▶

Oct 31, 2022 479 likes •820 views

LES STENTS BIORESORBABLES: UN AVENIR ? Ren Koning St Hilaire, Rouen (Circ Res. 2017;120:1341-1352. DOI: 10.1161/CIRCRESAHA.117.310275.) Septembre 2017 POURQUOI RK Y CROIS ENCORE? Baseline 6 Months 2 Years 5 Years Cohort B OCT images

SLIDE 1

LES STENTS BIORESORBABLES: UN AVENIR ?

René Koning – St Hilaire, Rouen

SLIDE 2

SLIDE 3

(Circ Res. 2017;120:1341-1352. DOI: 10.1161/CIRCRESAHA.117.310275.)

SLIDE 4

Septembre 2017

SLIDE 5

POURQUOI RK Y CROIS ENCORE?

SLIDE 6

Baseline 6 Months 2 Years 5 Years

Cohort B OCT images - courtesy of RJ van Geuns, Erasmus Medical Center, Netherlands De Bruyne, B. TCT 2014

SLIDE 7

On a voulu aller trop vite!

SLIDE 8

EuroIntervention 2019;15:28-30

SLIDE 9

SLIDE 10

S. ELLIS

SLIDE 11

FIN DU CONCEPT BIORESORBABLE ?

SLIDE 12

Mammaire Interne Gauche – IVA implantée il y a 35 ans…

SLIDE 13

(?)

LIMITES DES

SLIDE 14

EXAMINATION: 5-year results of a randomised trial (STEMI)

Lancet 2016; 387: 357–66, M Sabate.

SLIDE 15

15 ANS PLUS TARD!

11/09/2001 NEOATHEROME

SLIDE 16

NEO-ATHEROME

A Lipid-laden neointima. B Neointima with calcification

S.Y. Lee, Circ Cardiovasc Interv. 2015;

SLIDE 17

S.Y. Lee, Circ Cardiovasc Interv. 2015;

SLIDE 18

SLIDE 19

“The reason to persevere is not because of any expectation that scaffolds can beat metal stents in the intermediate term, but the concern that metal stents will begin to produce significant adverse events many years after implantation. That will have to become a demonstrated reality rather than a hypothetical speculation for bioresorbable scaffolds to replace metal stents.”

“And we know that metallic DES from years 3 to 10, and probably for the life of the patient, have about a 2-3% per year rate of TLF. So if Absorb or a bioresorbable scaffold can capture back a 1% or a half percent of those events on a per year benefit, then it won’t be many years at all before it makes up that early difference.” G. STONE,2017

SLIDE 20

ESPOIR !

SLIDE 21

SLIDE 22

PRE DILATATION 100% OPTIMAL SIZNG OCT 100% POST DILATATION 100%

SUIVI A 1 AN (N = 135)

Circulation Journal doi: 10.1253/circj.CJ-19-0636

SLIDE 23

Pas de différence de mortalité

SLIDE 24

ABSORB II à 4 ans

Pas de Thrombose entre 3 et 4 ans !

SLIDE 25

MACE and BVS THROMBOSIS INCIDENCE RATES

MACE incidence rate

(for 1000 patient-years)

Definite or probable BVS thrombosis incidence rate

(for 1000 patient-years)

FRANCE ABSORB 3 ANS

EUROPCR 2019

SLIDE 26

Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up A Systematic Meta-analysis and Individual Patient Data Pooled Study

G. Stone…. .P. Serruys

(JAMA 2019)

SLIDE 27

(Circ Res. 2017;120:1341-1352. DOI: 10.1161/CIRCRESAHA.117.310275.)

SLIDE 28

(Circ Res. 2017;120:1341-1352. DOI: 10.1161/CIRCRESAHA.117.310275.)

SLIDE 29

M HAUDE

SLIDE 30

M HAUDE

SLIDE 31

Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial, Ashok Seth,…. EuroIntervention 2019;15:607-614.

SLIDE 32